Table II.
β1 and β2-AR analysis in pediatric brain tumors.
| mRNA expression levels (ΔΔCt)
|
Immunohistochemistry
|
|||
|---|---|---|---|---|
| Sample | β1 receptor | β2 receptor | β1 receptor | β2 receptor |
| MB1 | 9.598 | 8.345 | 2 | 2 |
| MB2 | −3.968 | −4.528 | 1 | 2 |
| MB3 | 11.193 | 8.451 | 2 | 2 |
| MB4 | 6.785 | 4.891 | 1 | 2 |
| MB5 | 9.721 | 7.293 | 2 | 2 |
| EP1 | 5.611 | 5.637 | 2 | 2 |
| EP2 | −7.911 | −9.264 | 1 | 2 |
| EP3 | 11.291 | 6.421 | 1 | 2 |
| EP4 | 7.141 | 7.551 | 1 | 2 |
| EP5 | 6.525 | 8.061 | 2 | 2 |
| GBM1 | 6.046 | 5.846 | 1 | 2 |
| GBM2 | 7.751 | 8.180 | 2 | 2 |
| U87MG | 12.59 | 5.846 | ||
| DAOY | 6.046 | 8.18 | ||
| T98G | 7.141 | 8.88 | ||
| Human ref. | 12.698 | 9.887 | ||
β1 and β2 mRNA expression in tumor samples standardized to GAPDH (mean values from three replicates). MB, medulloblastoma; EP, ependymoma; GBM, glioblastoma multiforme. Human ref, universal human reference RNA (Stratagene); U87MG, glioblastoma-astrocytoma; DAOY, medulloblastoma; T98G, glioblastoma multiforme. Immunohistochemistry score: 0, ≤10%; 1, >10% and <50%; 2, >50% positive tumor cells.